Cleo Diagnostics Files Patents for Ovarian Cancer Screening Test
Key points
- Cleo Diagnostics files two provisional patent applications
- Protects intellectual property related to ovarian cancer screening
- Patents filed ahead of expected proof-of-concept data in Q4 CY2026
Full summary
Cleo Diagnostics Ltd has filed two new provisional patent applications to protect intellectual property arising from its ovarian cancer screening test. The filings establish priority around candidate biomarker combinations for early detection. The company plans to file an international application under the Patent Cooperation Treaty (PCT) within 12 months. These patents are filed ahead of the expected initial proof-of-concept screening data in Q4 CY2026. The development of the screening test builds on the company's biomarker platform and clinical expertise from its Pre-Surgical Ovarian Cancer Test program, which is progressing towards FDA submission.
Outlook
Cleo Diagnostics Ltd intends to expand its existing IP portfolio and apply its biomarker technology across multiple applications of the ovarian cancer detection pathway.
Summary generated by a large language model. Please interpret with care.